Equities

Surgical Science Sweden AB

Surgical Science Sweden AB

Actions
  • Price (EUR)10.32
  • Today's Change0.44 / 4.45%
  • Shares traded400.00
  • 1 Year change-25.00%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year Surgical Science Sweden AB grew revenues 10.01% from 802.54m to 882.85m while net income improved 24.47% from 187.97m to 233.97m.
Gross margin68.51%
Net profit margin23.59%
Operating margin17.63%
Return on assets4.00%
Return on equity4.36%
Return on investment4.26%
More ▼

Cash flow in SEKView more

In 2023, Surgical Science Sweden AB increased its cash reserves by 46.26%, or 200.63m. The company earned 238.29m from its operations for a Cash Flow Margin of 26.99%. In addition the company generated 15.85m cash from financing while 44.13m was spent on investing.
Cash flow per share5.00
Price/Cash flow per share24.20
Book value per share90.02
Tangible book value per share15.48
More ▼

Balance sheet in SEKView more

Surgical Science Sweden AB has a strong Balance Sheet and has consistently grown its cash reserves over the last Four years to total 634.37m.
Current ratio4.15
Quick ratio3.46
Total debt/total equity0.00
Total debt/total capital0.00
More ▼

Growth rates in SEK

SmartText is unavailable
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
-15.62
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.